Big Moving Stock keep track of the biggest moving stocks in the market.
The Hot Industries
Electric Utilities 1
REIT - Healthcare Facilities 1
Toys & Games 1
The Hot Sectors
Consumer Goods 1
ARIA Ariad Pharmaceuticals Inc.
ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing additional molecularly targeted therapies to treat patients with blood cancers and solid tumors. Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States for the treatment of adult patients with chronic, accelerated, or blast phase chronic myeloid leukemia, who are resistant or intolerant to prior TKI therapy, as well as for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to prior TKI therapy. Its product pipeline consists of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers; and AP1903, a small-molecule dimerizer drug. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus, for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.
Kings Cross to welcome rock star royalty15 Oct 2014, 1:01 pmThe X Studio aims to bring A-list celebrities into Sydney's Kings Cross to record, broadcast and party.
ARIAD's Iclusig Gains Positive Recommendation from PRAC - Analyst Blog14 Oct 2014, 4:32 pmARIAD's Iclusig Gains Positive Recommendation from PRAC - Analyst Blog
ARIAD's Iclusig Gains Positive Recommendation from PRAC14 Oct 2014, 2:55 pmAriad Pharmaceuticals Inc. (ARIA) announced that the PRAC issued a positive feedback in favor of Iclusig and that it can be continued to be used in Europe.
Amgen's Blinatumomab Gets Priority Review in the U.S. - Analyst Blog13 Oct 2014, 5:31 pmInvestors in the pharma biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give
Fat Lady Is About to Sing, According to the Charts8 Oct 2014, 2:42 pmToday’s rally doesn’t erase the bearish signals from recent market action, including small stock weakness.
ARIAD Gets Breakthrough Therapy Designation for AP26113 - Analyst Blog6 Oct 2014, 5:30 pmARIAD Gets Breakthrough Therapy Designation for AP26113 - Analyst Blog
ARIAD Gets Breakthrough Therapy Designation for AP261136 Oct 2014, 2:55 pmAriad Pharmaceuticals Inc. (ARIA) announced that the FDA has granted Breakthrough Therapy designation to its lung cancer candiadate, AP26113 for the treatment of ALK+ non-small cell lung cancer (NSCLC)....
Why Ariad Pharmaceuticals (ARIA) Stock Is Spiking Today2 Oct 2014, 9:59 amNEW YORK (TheStreet) -- Ariad Pharmaceuticals shares are up 8.6% to $5.74 on Thursday after the company announced that its experimental lung cancer drug received a "breakthrough therapy" designation from the FDA. A "breakthrough therapy designation" means that the FDA can fast track the review process for aadrug that shows evidence of being an improvement of current treatments for patients with ...
Bulls Target Ariad Pharmaceuticals, Inc. (ARIA) Amid Drug News2 Oct 2014, 9:44 amAriad Pharmaceuticals, Inc. (NASDAQ:ARIA) gapped higher this morning on news that its lung cancer drug, ... ( Read More )
Amgen Files Blinatumomab Marketing Application in U.S. - Analyst Blog23 Sep 2014, 5:51 pmAmgen ( AMGN ) announced that it has submitted a Biologics License Application (BLA) to the FDA for its oncology candidate, blinatumomab. The company is looking to get the candidate approved for the treatment of adults suffering from Philadelphia